FDA Removes Zantac (Ranitidine) from Market for Potential Carcinogen Exposure

The U.S. Food & Drug Administration (FDA) has requested that all over-the-counter and prescription ranitidine medications, brand name Zantac, be removed from the shelves immediately. All consumers are also advised to immediately stop taking Zantac and ranitidine medications, and consult with their physicians about disposing of their medications.

In 2019, independent laboratory testing identified the presence of N-Nitrosodimethylamine (NDMA), a known carcinogen, in ranitidine medications. Carcinogens are substances which can cause cancer. This contaminant can increase over time when stored in higher temperatures, causing the NDMA to reach levels that could be unsafe.

If you believed you may have been exposed to increased levels of NDMA from an OTC or prescription ranitidine medication, Eichen Crutchlow Zaslow, LLP wants to help. Please fill out the contact form above or call 732-777-0100 to schedule your free consultation.